Internalization of eNOS and NO delivery to subcellular targets determine agonist-induced hyperpermeability

Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6849-53. doi: 10.1073/pnas.0812694106. Epub 2009 Apr 2.

Abstract

The molecular mechanisms of endothelial nitric oxide synthase (eNOS) regulation of microvascular permeability remain unresolved. Agonist-induced internalization may have a role in this process. We demonstrate here that internalization of eNOS is required to deliver NO to subcellular locations to increase endothelial monolayer permeability to macromolecules. Using dominant-negative mutants of dynamin-2 (dyn2K44A) and caveolin-1 (cav1Y14F), we show that anchoring eNOS-containing caveolae to plasma membrane inhibits hyperpermeability induced by platelet-activating factor (PAF), VEGF in ECV-CD8eNOSGFP (ECV-304 transfected cells) and postcapillary venular endothelial cells (CVEC). We also observed that anchoring caveolar eNOS to the plasma membrane uncouples eNOS phosphorylation at Ser-1177 from NO production. This dissociation occurred in a mutant- and cell-dependent way. PAF induced Ser-1177-eNOS phosphorylation in ECV-CD8eNOSGFP and CVEC transfected with dyn2K44A, but it dephosphorylated eNOS at Ser-1177 in CVEC transfected with cav1Y14F. Interestingly, dyn2K44A eliminated NO production, whereas cav1Y14F caused reduction in NO production in CVEC. NO production by cav1Y14F-transfected CVEC occurred in caveolae bound to the plasma membrane, and was ineffective in causing an increase in permeability. Our study demonstrates that eNOS internalization is required for agonist-induced hyperpermeability, and suggests that a mechanism by which eNOS is activated by phosphorylation at the plasma membrane and its endocytosis is required to deliver NO to subcellular targets to cause hyperpermeability.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Capillary Permeability / drug effects*
  • Cattle
  • Caveolae / drug effects
  • Caveolae / metabolism
  • Endocytosis / drug effects*
  • Endothelial Cells / cytology
  • Endothelial Cells / drug effects
  • Endothelial Cells / enzymology
  • Enzyme Activation / drug effects
  • Nitric Oxide / metabolism*
  • Nitric Oxide Synthase Type III / metabolism*
  • Platelet Activating Factor / pharmacology*
  • Recombinant Fusion Proteins / metabolism
  • Subcellular Fractions / drug effects
  • Subcellular Fractions / enzymology
  • Vascular Endothelial Growth Factor A / pharmacology

Substances

  • Platelet Activating Factor
  • Recombinant Fusion Proteins
  • Vascular Endothelial Growth Factor A
  • Nitric Oxide
  • Nitric Oxide Synthase Type III